Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Acidosis
Ethanol metabolism, cirrhosis and alcoholism.
Acute Kidney Injury
Changes in 25-hydroxyvitamin D3 alpha- and 24-hydroxylase activities of kidney cells isolated from rats with either unilateral kidney damage or acute renal insufficiency.
Adenocarcinoma
Cancer biomarker AKR1B10 and carbonyl metabolism.
Adenocarcinoma of Lung
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Adenocarcinoma of Lung
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Adrenocortical Carcinoma
Homeobox A5 activates p53 pathway to inhibit proliferation and promote apoptosis of adrenocortical carcinoma cells by inducing Aldo-Keto reductase family 1 member B10 expression.
Arthritis
Effect of adjuvant polyarthritis on liver alcohol dehydrogenase in the rat.
Ascorbic Acid Deficiency
Vitamin C. Biosynthesis, recycling and degradation in mammals.
Astrocytoma
[Effect of AKR1A1 knock-down on H2;O2; and 4-hydroxynonenal-induced cytotoxicity in human 1321N1 astrocytoma cells].
Breast Neoplasms
AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program.
Breast Neoplasms
AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
Breast Neoplasms
AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Breast Neoplasms
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
Breast Neoplasms
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Breast Neoplasms
Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells.
Breast Neoplasms
An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Breast Neoplasms
Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone-metabolizing enzyme AKR1C (aldo-keto reductase) family caused by estradiol.
Breast Neoplasms
Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.
Breast Neoplasms
Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer.
Breast Neoplasms
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Breast Neoplasms
SMAR1 regulates free radical stress through modulation of AKR1a4 enzyme activity.
Carcinogenesis
Adrenal tumorigenesis targeted by the corticotropin-regulated promoter of the aldo-keto reductase AKR1B7 gene in transgenic mice.
Carcinogenesis
Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis.
Carcinogenesis
Expression of AKR1B10 as an independent marker for poor prognosis in human oral squamous cell carcinoma.
Carcinogenesis
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Carcinogenesis
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Carcinogenesis
Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients.
Carcinogenesis
Sulindac inhibits pancreatic carcinogenesis in LSL-KrasG12D-LSL-Trp53R172H-Pdx-1-Cre mice via suppressing aldo-keto reductase family 1B10 (AKR1B10).
Carcinoma
Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells.
Carcinoma
AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-?B axis in nasopharyngeal carcinoma.
Carcinoma
AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Carcinoma
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Carcinoma
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Carcinoma
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Carcinoma
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Carcinoma
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Carcinoma
Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma.
Carcinoma
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
Carcinoma
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Carcinoma
Overexpression and oncogenic function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic carcinoma.
Carcinoma
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas.
Carcinoma
The Expression and Clinical Significance of Aldo-Keto Reductase 1 Member B1 in Gastric Carcinoma.
Carcinoma, Ductal
Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity.
Carcinoma, Embryonal
Characterization of the functional gene encoding mouse class III alcohol dehydrogenase (glutathione-dependent formaldehyde dehydrogenase) and an unexpressed processed pseudogene with an intact open reading frame.
Carcinoma, Embryonal
The role of alcohol dehydrogenase in retinoic acid homeostasis and fetal alcohol syndrome.
Carcinoma, Hepatocellular
A Large-Scale Multicenter Study Validates AKR1B10 as a New Prevalent Serum Marker for Detection of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Abnormal membrane phospholipid content in subcellular fractions from the Morris 7777 hepatoma.
Carcinoma, Hepatocellular
AKR1B10 expression by immunohistochemistry in surgical resections and fine needle aspiration cytology material in patients with cystic pancreatic lesions; potential for improved nonoperative diagnosis.
Carcinoma, Hepatocellular
AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.
Carcinoma, Hepatocellular
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Carcinoma, Hepatocellular
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Carcinoma, Hepatocellular
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Carcinoma, Hepatocellular
Bioequivalence studies of tibolone in premenopausal women and effects on expression of the tibolone-metabolizing enzyme AKR1C (aldo-keto reductase) family caused by estradiol.
Carcinoma, Hepatocellular
Dietary Se deficiency dysregulates metabolic and cell death signaling in aggravating the AFB1 hepatotoxicity of chicks.
Carcinoma, Hepatocellular
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Carcinoma, Hepatocellular
Expression of aldo-keto reductase family 1 member b10 in the early stages of human hepatocarcinogenesis.
Carcinoma, Hepatocellular
Expression of differentiated functions in hepatoma cell hybrids. VI. Extinction and re-expression of liver alcohol dehydrogenase.
Carcinoma, Hepatocellular
High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
Carcinoma, Hepatocellular
High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Carcinoma, Hepatocellular
Induction of alcohol dehydrogenase activity and mRNA in hepatoma cells by dexamethasone.
Carcinoma, Hepatocellular
Metabolic enzyme induction by HepG2 cells exposed to oxygenated and nonoxygenated polycyclic aromatic hydrocarbons.
Carcinoma, Hepatocellular
Metabolism of gamma hydroxybutyrate in human hepatoma HepG2 cells by the aldo-keto reductase AKR1A1.
Carcinoma, Hepatocellular
New data on kinetics of lipid peroxidation in experimental hepatomas and preneoplastic nodules.
Carcinoma, Hepatocellular
Prognostic Significance of 14-3-3?, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Proteome analysis of rat hepatomas: carcinogen-dependent tumor-associated protein variants.
Carcinoma, Hepatocellular
Purification and catalytic properties of liver alcohol dehydrogenase isoenzymes in patients with hepatoma in Nigeria.
Carcinoma, Hepatocellular
Quantitative Evaluation of Aldo-keto Reductase Expression in Hepatocellular Carcinoma (HCC) Cell Lines.
Carcinoma, Hepatocellular
Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Carcinoma, Hepatocellular
Studies on lipid peroxidation in normal and tumour tissues. The Yoshida rat liver tumour.
Carcinoma, Hepatocellular
Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
Carcinoma, Hepatocellular
[Aldo-keto reductase family 1 B10 participates in the regulation of hepatoma cell cycle through p27/p-Rb signaling pathway].
Carcinoma, Hepatocellular
[Enzymes metabolizing xenobiotics in spontaneous tumors in mice]
Carcinoma, Intraductal, Noninfiltrating
Overexpression of Aldo-keto reductase family 1 B10 protein in ductal carcinoma in situ of the breast correlates with HER2 positivity.
Carcinoma, Non-Small-Cell Lung
Activation of polycyclic aromatic hydrocarbon trans-dihydrodiol proximate carcinogens by human aldo-keto reductase (AKR1C) enzymes and their functional overexpression in human lung carcinoma (A549) cells.
Carcinoma, Non-Small-Cell Lung
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Carcinoma, Non-Small-Cell Lung
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Carcinoma, Ovarian Epithelial
Computational design of novel peptidomimetic inhibitors of cadherin homophilic interactions.
Carcinoma, Squamous Cell
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Carcinoma, Squamous Cell
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Carcinoma, Squamous Cell
Structure and promoter characterization of aldo-keto reductase family 1 B10 gene.
Cardiotoxicity
Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.
Cataract
Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase.
Cell Transformation, Neoplastic
AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker.
Chagas Disease
A role for trypanosomatid aldo-keto reductases in methylglyoxal, prostaglandin and isoprostane metabolism.
Colitis, Ulcerative
Impaired Barrier Function and Immunity in the Colon of Aldo-Keto Reductase 1B8 Deficient Mice.
Colonic Neoplasms
Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway.
Colonic Neoplasms
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Colonic Neoplasms
Inhibition of aldose reductase prevents angiogenesis in vitro and in vivo.
Colonic Neoplasms
Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.
Colonic Neoplasms
Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis.
Colorectal Neoplasms
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Colorectal Neoplasms
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Colorectal Neoplasms
Impaired Barrier Function and Immunity in the Colon of Aldo-Keto Reductase 1B8 Deficient Mice.
Colorectal Neoplasms
Impaired Self-Renewal and Increased Colitis and Dysplastic Lesions in Colonic Mucosa of AKR1B8-Deficient Mice.
Colorectal Neoplasms
Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.
Dehydration
Stopped-flow determination of the active form of acetaldehyde in the liver alcohol dehydrogenase catalyzed reaction.
Dementia
Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.
Diabetes Complications
Aldo-keto reductase and sorbitol dehydrogenase enzymes in Egyptian diabetic patients with and without proliferative diabetic retinopathy.
Diabetes Complications
Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives.
Diabetes Complications
Cooperative regulation of mouse aldose reductase (AKR1B3) gene transcription by Nrf2, TonEBP, and c-jun.
Diabetes Complications
Expression of human aldose and aldehyde reductases. Site-directed mutagenesis of a critical lysine 262.
Diabetes Complications
Functional genomic studies of aldo-keto reductases.
Diabetes Complications
High-resolution neutron protein crystallography with radically small crystal volumes: application of perdeuteration to human aldose reductase.
Diabetes Complications
Kinetic and structural characterization of the glutathione-binding site of aldose reductase.
Diabetes Complications
Reductive detoxification of acrolein as a potential role for aldehyde reductase (AKR1A) in mammals.
Diabetes Complications
The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10.
Diabetes Complications
Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes.
Diabetes Mellitus
Renal gene expression in embryonic and newborn diabetic mice.
Diabetes Mellitus
Targeting aldose reductase for the treatment of diabetes complications and inflammatory diseases: new insights and future directions.
Diabetes Mellitus, Experimental
[Status of the monooxygenase enzyme system in rat and rabbit organs in sugar diabetes and upon insulin administration]
Diabetes Mellitus, Type 2
Transcript Levels of Aldo-Keto Reductase Family 1 Subfamily C (AKR1C) Are Increased in Prostate Tissue of Patients with Type 2 Diabetes.
Diabetic Nephropathies
Relevance of aldo-keto reductase family members to the pathobiology of diabetic nephropathy and renal development.
Diabetic Retinopathy
Aldo-keto reductase and sorbitol dehydrogenase enzymes in Egyptian diabetic patients with and without proliferative diabetic retinopathy.
Digestive System Neoplasms
Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Down Syndrome
Development of a CART Model to Predict the Synthesis of Cardiotoxic Daunorubicinol in Heart Tissue Samples From Donors With and Without Down Syndrome.
Drug Hypersensitivity
Variability of the Genes Involved in the Cellular Redox Status and Their Implication in Drug Hypersensitivity Reactions.
Endometrial Neoplasms
Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.
Endometrial Neoplasms
Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening.
Epilepsy
Discovery of new inhibitors of aldo-keto reductase 1C1 by structure-based virtual screening.
Fatty Liver
Ethanol metabolism, cirrhosis and alcoholism.
Fibrosarcoma
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Gastrointestinal Neoplasms
Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-?-dependent mechanism.
Glioblastoma
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression.
Hepatitis B
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Hepatitis B
High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
Hepatitis C
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Hepatitis C
Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication.
Hepatitis C, Chronic
Up-regulated aldo-keto reductase family 1 member B10 in chronic hepatitis C: association with serum alpha-fetoprotein and hepatocellular carcinoma.
Hepatoblastoma
A nuclear protein, synthesized in growth-arrested human hepatoblastoma cells, is a novel member of the short-chain alcohol dehydrogenase family.
Huntington Disease
Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia.
Hyperglycemia
Ethanol metabolism, cirrhosis and alcoholism.
Hyperthyroidism
Thyroid hormone action on intermediary metabolism. Part III. Protein metabolism in hyper- and hypothyroidism.
Hypoglycemia
[Status of the monooxygenase enzyme system in rat and rabbit organs in sugar diabetes and upon insulin administration]
Infections
Drug metabolism in experimental tuberculosis: I. Changes in hepatic and pulmonary monooxygenase activities due to infection.
Infections
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Infections
Infection of barley with the parasitic fungus Blumeria graminis f.sp. hordei results in the induction of HvADH1 and HvADH2.
Infections
Rat liver alcohol dehydrogenase isozymes: influence of infection with Trypanosoma.
Influenza, Human
QSAR models based on quantum topological molecular similarity.
Influenza, Human
Quantum topological QSAR models based on the MOLMAP approach.
Keloid
The aldo-keto reductase AKR1B10 is upregulated in keloid epidermis, implicating retinoic acid pathway dysregulation in the pathogenesis of keloid disease.
Leukemia
Characterization of daunorubicin resistance in K562 leukemia cells lacking daunorubicin reductase activity.
Leukemia
Daunorubicin reductase activity in leukemia leukocyte homogenates.
Leukemia
High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.
Leukemia
Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis.
Leukemia
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-?-hydroxysteroid dehydrogenase (AKR1C3).
Leukemia
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
Leukemia
The monocytic differentiation of HL60 induced by rat kidney NADPH-linked high-Km aldehyde reductase protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Leukemia, Myeloid
The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs.
Leukemia, Myeloid, Acute
High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.
Leukemia, Myeloid, Acute
Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation.
Leukemia, Myeloid, Acute
Upregulation of AKR1C1 in mesenchymal stromal cells promotes the survival of acute myeloid leukaemia cells.
Lipedema
Aldo-Keto Reductase 1C1 (AKR1C1) as the First Mutated Gene in a Family with Nonsyndromic Primary Lipedema.
Liver Cirrhosis
Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Liver Cirrhosis, Alcoholic
Alterations of liver alcohol dehydrogenase and other hepatic enzymes in alcoholic cirrhosis.
Liver Cirrhosis, Alcoholic
Polymorphism of alcohol dehydrogenase, alcohol and aldehyde dehydrogenase activities: implication in alcoholic cirrhosis in white patients. The French Group for Research on Alcohol and Liver.
Liver Diseases
Aldo-keto reductase family 1 member B10 is associated with hepatitis B virus-related hepatocellular carcinoma risk.
Liver Diseases
Genetic polymorphism of liver alcohol dehydrogenase in Spanish subjects: significance of alcohol consumption and liver disease.
Liver Diseases
Immunohistochemistry Detects Increased Expression of Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) in Early-Stage Hepatocellular Carcinoma.
Liver Diseases
Impact of aldo-keto reductase family 1 member B10 on the risk of hepatitis C virus-related hepatocellular carcinoma.
Liver Diseases
Influence of liver disease and environmental factors on hepatic monooxygenase activity in vitro.
Liver Diseases
Monooxygenase enzyme activity in alcoholics with varying degrees of liver damage.
Liver Diseases, Alcoholic
Atypical liver alcohol dehydrogenase in the Spanish population: its relation with the development of alcoholic liver disease.
Liver Neoplasms
A novel AKR1C3 specific prodrug TH3424 with potent anti-tumor activity in liver cancer.
Liver Neoplasms
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Liver Neoplasms
Aldo-keto Reductase Family 1 Member B 10 Mediates Liver Cancer Cell Proliferation through Sphingosine-1-Phosphate.
Liver Neoplasms
Cancer biomarker AKR1B10 and carbonyl metabolism.
Lung Neoplasms
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Lung Neoplasms
Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.
Lung Neoplasms
Correction to Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Lung Neoplasms
Exposure to 9,10-phenanthrenequinone accelerates malignant progression of lung cancer cells through up-regulation of aldo-keto reductase 1B10.
Lung Neoplasms
Inhibiting proliferation and migration of lung cancer using small interfering RNA targeting on Aldo-keto reductase family 1 member B10.
Lung Neoplasms
Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Lung Neoplasms
Nitric oxide confers cisplatin resistance in human lung cancer cells through upregulation of aldo-keto reductase 1B10 and proteasome.
Lung Neoplasms
Protective roles of aldo-keto reductase 1B10 and autophagy against toxicity induced by p-quinone metabolites of tert-butylhydroquinone in lung cancer A549 cells.
Lung Neoplasms
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Lung Neoplasms
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Melanoma
A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma.
Melanoma
Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma.
Mesothelioma, Malignant
Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma.
Multiple Myeloma
LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.
Nasopharyngeal Carcinoma
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Neoplasm Metastasis
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
Neoplasm Metastasis
AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
Neoplasm Metastasis
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
Neoplasm Metastasis
Correction to Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Neoplasm Metastasis
Expression of AKR1C3 and CNN3 as markers for detection of lymph node metastases in colorectal cancer.
Neoplasm Metastasis
Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.
Neoplasm Metastasis
Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion.
Neoplasm Metastasis
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Neoplasms
A therapeutic method for the direct reprogramming of human liver cancer cells with only chemicals.
Neoplasms
ADH-1 in the treatment of metastatic adrenocortical carcinoma--case report.
Neoplasms
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
Neoplasms
AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model.
Neoplasms
AKR1B10 activates diacylglycerol (DAG) second messenger in breast cancer cells.
Neoplasms
AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling.
Neoplasms
AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-?B signaling pathway.
Neoplasms
AKR1B10 promotes breast cancer metastasis through integrin ?5/?-catenin mediated FAK/Src/Rac1 signaling pathway.
Neoplasms
AKR1B10-inhibitory Selaginella tamariscina extract and amentoflavone decrease the growth of A549 human lung cancer cells in vitro and in vivo.
Neoplasms
AKR1C enzymes sustain therapy resistance in paediatric T-ALL.
Neoplasms
AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects.
Neoplasms
AKR1C3 Is Associated with Better Survival of Patients with Endometrial Carcinomas.
Neoplasms
Aldo-Keto Reductase 1B10 and Its Role in Proliferation Capacity of Drug-Resistant Cancers.
Neoplasms
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Neoplasms
Aldo-keto reductase 1C3 (AKR1C3) is associated with the doxorubicin resistance in human breast cancer via PTEN Loss.
Neoplasms
Aldo-Keto Reductase Family 1 B1 Inhibitors: Old Drugs with New Perspectives.
Neoplasms
Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells.
Neoplasms
Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention.
Neoplasms
Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma.
Neoplasms
Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Neoplasms
Aldo-keto reductase family 1 member C1 regulates the osteogenic differentiation of human ASCs by targeting the progesterone receptor.
Neoplasms
Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Neoplasms
Aldose reductase (AKR1B) deficiency promotes phagocytosis in bone marrow derived mouse macrophages.
Neoplasms
Cadherins as novel targets for anti-cancer therapy.
Neoplasms
Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10.
Neoplasms
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.
Neoplasms
Comparison of crystal structures of human type 3 3alpha-hydroxysteroid dehydrogenase reveals an "induced-fit" mechanism and a conserved basic motif involved in the binding of androgen.
Neoplasms
Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
Neoplasms
Design, synthesis and evaluation of caffeic acid phenethyl ester-based inhibitors targeting a selectivity pocket in the active site of human aldo-keto reductase 1B10.
Neoplasms
DNA repair pathway activation features in follicular and papillary thyroid tumors, interrogated using 95 experimental RNA sequencing profiles.
Neoplasms
Down-regulation of aldo-keto reductase AKR1B10 gene expression by a phorbol ester via the ERK/c-Jun signaling pathway.
Neoplasms
Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Neoplasms
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Neoplasms
Emergence of the Dedifferentiated Phenotype in Hepatocyte-Derived Tumors in Mice: Roles of Oncogene-Induced Epigenetic Alterations.
Neoplasms
Establishment and characterization of mouse mammary carcinoma cell lines expressing RET with a multiple endocrine neoplasia 2A mutation.
Neoplasms
Gateways to clinical trials.
Neoplasms
Genomic alterations in breast cancer patients in betel quid and non betel quid chewers.
Neoplasms
Heat shock protein 90-? mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes.
Neoplasms
High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma.
Neoplasms
High expression of aldo-keto reductase 1B10 is an independent predictor of favorable prognosis in patients with hepatocellular carcinoma.
Neoplasms
IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors.
Neoplasms
Identification of a role for serum aldo-keto reductase family 1 member B10 in early detection of hepatocellular carcinoma.
Neoplasms
Improvement of chemosensitivity and inhibition of migration via targeting tumor epithelial-to-mesenchymal transition cells by ADH-1-modified liposomes.
Neoplasms
Inhibition of human aldose reductase-like protein (AKR1B10) by ?- and ?-mangostins, major components of pericarps of mangosteen.
Neoplasms
Inhibitors of aldehyde dehydrogenases of the 1A subfamily as putative anticancer agents: Kinetic characterization and effect on human cancer cells.
Neoplasms
Inhibitors of type 5 17?-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights.
Neoplasms
Inhibitory effects of polyphenols isolated from Rhus verniciflua on Aldo-keto reductase family 1 B10.
Neoplasms
Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Neoplasms
Involvement of the aldo-keto reductase, AKR1B10, in mitomycin-c resistance through reactive oxygen species-dependent mechanisms.
Neoplasms
Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers.
Neoplasms
LCRF-0006, a small molecule mimetic of the N-cadherin antagonist peptide ADH-1, synergistically increases multiple myeloma response to bortezomib.
Neoplasms
Long-chain fatty acids inhibit human members of the aldo-keto reductase 1C subfamily.
Neoplasms
Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma.
Neoplasms
Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity.
Neoplasms
Melphalan in regional chemotherapy for locally recurrent metastatic melanoma.
Neoplasms
Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation.
Neoplasms
Metabolic characteristics and enflurane defluorination of cytochrome P450-dependent monooxygenases in human hepatocellular carcinoma.
Neoplasms
Methyl Jasmonate: Putative Mechanisms of Action on Cancer Cells Cycle, Metabolism, and Apoptosis.
Neoplasms
Modulated expression of genes encoding estrogen metabolizing enzymes by G1-phase cyclin-dependent kinases 6 and 4 in human breast cancer cells.
Neoplasms
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-?-hydroxysteroid dehydrogenase (AKR1C3).
Neoplasms
Murine aldo-keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10.
Neoplasms
N-cadherin as a therapeutic target in cancer.
Neoplasms
N-cadherin in neuroblastoma disease: expression and clinical significance.
Neoplasms
Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.
Neoplasms
Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion.
Neoplasms
Overcoming drug resistance with functional mesoporous titanium dioxide nanoparticles combining targeting, drug delivery and photodynamic therapy.
Neoplasms
Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker.
Neoplasms
Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer.
Neoplasms
Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors.
Neoplasms
Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis.
Neoplasms
Prenatal alcohol exposure alters phosphorylation and glycosylation of proteins in rat offspring liver.
Neoplasms
Prognostic value of aldo-keto reductase family 1 member B10 (AKR1B10) in digestive system cancers: A meta-analysis.
Neoplasms
Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma.
Neoplasms
Proteomics detection of S100A6 in tumor tissue interstitial fluid and evaluation of its potential as a biomarker of cholangiocarcinoma.
Neoplasms
Quantitative analysis of the human AKR family members in cancer cell lines using the mTRAQ/MRM approach.
Neoplasms
Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Neoplasms
Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma.
Neoplasms
Renal gene expression in embryonic and newborn diabetic mice.
Neoplasms
Selective inhibition of human type-5 17?-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
Neoplasms
Selective inhibition of the tumor marker AKR1B10 by antiinflammatory N-phenylanthranilic acids and glycyrrhetic acid.
Neoplasms
Selective inhibition of the tumor marker aldo-keto reductase family member 1B10 by oleanolic acid.
Neoplasms
Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Neoplasms
SMAR1 regulates free radical stress through modulation of AKR1a4 enzyme activity.
Neoplasms
Stimulation of N-cadherin-dependent neurite outgrowth by small molecule peptide mimetic agonists of the N-cadherin HAV motif.
Neoplasms
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
Neoplasms
Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.
Neoplasms
Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.
Neoplasms
Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3.
Neoplasms
Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells.
Neoplasms
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
Neoplasms
The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10.
Neoplasms
The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoateinduced esophageal squamous cell carcinoma cell death.
Neoplasms
Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.
Neoplasms
Transcriptomic responses of cancerous and noncancerous human colon cells to sulforaphane and selenium.
Neuralgia
Novel peptide mimetic small molecules of the HAV motif in N-cadherin inhibit N-cadherin-mediated neurite outgrowth and cell adhesion.
Neuroblastoma
Synthesis and catabolism of gamma-hydroxybutyrate in SH-SY5Y human neuroblastoma cells: role of the aldo-keto reductase AKR7A2.
Non-alcoholic Fatty Liver Disease
Serum aldo-keto reductase family 1 member B10 predicts advanced liver fibrosis and fatal complications of nonalcoholic steatohepatitis.
Obesity
[Aldehyde reductase activity and blood aldo-keto reductase spectrum in adolescents with neuroendocrine obesity].
Ovarian Neoplasms
Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer.
Pancreatic Neoplasms
?2-AR regulates the expression of AKR1B1 in human pancreatic cancer cells and promotes their proliferation via the ERK1/2 pathway.
Pancreatic Neoplasms
ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
AKR1C enzymes sustain therapy resistance in paediatric T-ALL.
Prostatic Hyperplasia
AKR1B10 expression in benign prostatic hyperplasia and its related mechanism.
Prostatic Neoplasms
3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: Highly Potent and Selective Inhibitors of the Type 5 17-?-Hydroxysteroid Dehydrogenase AKR1C3.
Prostatic Neoplasms
AKR1C2 and AKR1C3 mediated prostaglandin D2 metabolism augments the PI3K/Akt proliferative signaling pathway in human prostate cancer cells.
Prostatic Neoplasms
Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Inhibitory Interplay of SULT2B1b Sulfotransferase with AKR1C3 Aldo-keto Reductase in Prostate Cancer.
Prostatic Neoplasms
PTHrP stimulates prostate cancer cell growth and upregulates aldo-keto reductase 1C3.
Prostatic Neoplasms
Roles of aldo-keto reductase 1B10 and 1C3 and ATP-binding cassette transporter in docetaxel tolerance.
Prostatic Neoplasms
Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Prostatic Neoplasms
Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism.
Riboflavin Deficiency
Effects of riboflavin deficiency on lipid peroxidation of rat liver microsomes.
Riboflavin Deficiency
Lipid metabolism in riboflavin-deficient rats. 2. Mitochondrial fatty acid oxidation and the microsomal desaturation pathway.
Sarcoma, Yoshida
Effect of nicotinamide on hepatic microsomal drug metabolising system in tumour-bearing rats and mice.
Seizures
Diet composition, alcohol utilization, and dependence.
Sepsis
Aldose reductase (AKR1B) deficiency promotes phagocytosis in bone marrow derived mouse macrophages.
Squamous Cell Carcinoma of Head and Neck
Increased salivary AKR1B10 level: Association with progression and poor prognosis of oral squamous cell carcinoma.
Stomach Neoplasms
Acquisition of doxorubicin resistance facilitates migrating and invasive potentials of gastric cancer MKN45 cells through up-regulating aldo-keto reductase 1B10.
Stomach Neoplasms
Aldo-keto reductase 1B10 promotes development of cisplatin resistance in gastrointestinal cancer cells through down-regulating peroxisome proliferator-activated receptor-?-dependent mechanism.
Stomach Neoplasms
[Expression of aldo-keto reductase family 1 member B10 in gastric cancer tissues and its clinical significance].
Stroke
Effect of C7 Modifications on Benzothiadiazine-1,1-dioxide Derivatives on Their Inhibitory Activity and Selectivity toward Aldose Reductase.
Tardive Dyskinesia
Extrapyramidal disorders: a possible underlying mechanism.
Thiamine Deficiency
Acceleration of ethanol metabolism by past thiamine deficiency.
Tuberculosis
Biotransformation and bioactivation reactions - 2015 literature highlights.
Tuberculosis
Drug metabolism in experimental tuberculosis: I. Changes in hepatic and pulmonary monooxygenase activities due to infection.
Uremia
Effect of uremia on rates of ethanol disappearance from the blood and on the activities of the ethanol-oxidizing enzymes.
Urinary Bladder Neoplasms
Aldo-keto reductase 1C1 induced by interleukin-1? mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
Uterine Cervical Neoplasms
Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.
Uterine Diseases
Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases.
Vitamin A Deficiency
Effects of vitamin A deficiency on rat liver alcohol dehydrogenase expression and alcohol elimination rate in rats.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1.1.1.2 alcohol dehydrogenase (NADP+)
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
